Please provide your email address to receive an email when new articles are posted on . A phase 2 study found micro-doses of latanoprost were consistent with standard drops in lowering IOP and were ...
The US Food and Drug Administration (FDA) has approved a once-daily treatment with netarsudil and latanoprost ophthalmic solution (Rocklatan, Aerie Pharmaceuticals) to decrease elevated intraocular ...
The US Food and Drug Administration (FDA) has approved latanoprost ophthalmic emulsion 0.005% (Xelpros, Sun Pharmaceuticals) to reduce elevated intraocular pressure (IOP) in patients with open-angle ...
MUMBAI, India & PRINCETON, N.J.--(BUSINESS WIRE)--Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries ...
Peapack, New Jersey (May 2, 2002) - Data presented for the first time at the XXIXth International Congress of Ophthalmology in Sydney, Australia, show that long-term (5-year) adjunctive treatment with ...
SHIRLEY, N.Y. — American Regent has launched a generic drug for relieving pressure inside the eye, the company said. American Regent announced the availability of latanoprost ophthalmic solution in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results